Molecular Docking Synthesis and Pharmacological Screening of Peroxisome Proliferator -activated receptor (PPAR) Y Agonists for treatment of type 2 Diabetes

Abstract

Diabetes currently affects over 425 million adults in the world of age group of 20 to 79 years. By 2045 this will rise up to 629 million. The people with living type 2 diabetes their proportion is higher. 79% adults whom are suffering from this disease are living in low to middle income countries. Diabetes caused 4 million deaths. 352 million people are risk of developing type 2 diabetes. In the treatment of type 2 diabetes the drugs which were used were Rosiglitazone and Pioglitazone. And the receptor which is responsible for it is Peroxisome proliferator-activated receptors (PPAR) γ. But after the frequent use of the mentioned drugs it has been proven that they cause severe side effects and life threat was become more. That’s why development of new molecule for the treatment of type 2 diabetes is become very important. Gallic acid containing gallo tannins showed promising effect in the treatment of type 2 diabetes. It is extracted from Terminalia chebula and many other plants. Docking study was done by using PPAR gamma receptor ligand and the PDB id was 4EMA. Docking of Gallic acid was done in reference to Rosiglitazone and Pioglitazone. Which had shown the better GOLD SCORE of 44.30 than the older once. Now the Gallic acid if it has a good anti diabetic activity then if its derivatives are there then they may be give better anti diabetic activity. So the Gallic acid derivatives were docked and they had given better interactions with the standard ligand with better GOLD SCORE of 59 and 57 respectively. So according to that different Gallic acid derivatives were synthesized and confirmation was done by using MASS analysis.